On the heels of an Eli Lilly deal, NextCure’s hot hand in I/O attracts a $93M trans-Pacific venture round
Last week Eli Lilly showed their faith in NextCure by fronting an immuno-oncology collaboration with $40 million in upfront and equity cash. This week the biotech is coming out with a $93 million raise to help illustrate how trendy I/O remains in venture circles — especially if you promise to break some new ground in the field.
Experts in exploring the surface of cells in the development of new cancer therapies, their lead drug is in preclinical development. NC318 targets S15, which the company believes helps myeloid cells survive and thrive, while tapping down on the T cell responses that are now being driven by a host of drugs in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
